Despite record revenue for its latest quarter, the medical device maker's shares sank 8% following its earnings release. But its next stage of growth is coming.Abiomed (NASDAQ: ABMD) reported its fiscal 2021 fourth-quarter earnings last week, with 17% year-over-year revenue growth of $243 million ...

https://www.fool.com/investing/2021/05/04/abiomed-to-shareholders-patience-please/?source=iedfolrf0000001

#fool